The Ideal Way to Use Quizartinib to Treat AML
Mark J. Levis, MD, PhD, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).
Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).
Clinical Pearls:
- The ideal way to use a FLT3 inhibitor is to introduce it upfront with induction therapy in a newly diagnosed patient with FLT3-ITD AML
- Studies using “not as effective” FLT3 inhibitors still show a considerable amount of efficacy with this procedure
- Patients should be treated into remission until the patient can receive an allogeneic transplant and then a FLT3 inhibitor
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
